메뉴 건너뛰기




Volumn 2013, Issue , 2013, Pages

Pharmacogenetics of oral antidiabetic drugs

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ATM PROTEIN; CHLORPROPAMIDE; CHYMOTRYPSINOGEN; CYTOCHROME P450 2C9; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INCRETIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; MEGLITINIDE; METFORMIN; MITIGLINIDE; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; ORGANIC CATION TRANSPORTER 1; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TRANSCRIPTION FACTOR 7 LIKE 2; TROGLITAZONE;

EID: 84890094831     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/686315     Document Type: Review
Times cited : (37)

References (86)
  • 2
    • 70349578557 scopus 로고    scopus 로고
    • The diagnosis and management of monogenic diabetes in children and adolescents
    • supplement 12 2-s2.0-70349578557 10.1111/j.1399-5448.2009.00571.x
    • Hattersley A., Bruining J., Shield J., Njolstad P., Donaghue K. C., The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric Diabetes 2009 10 supplement 12 33 42 2-s2.0-70349578557 10.1111/j.1399-5448.2009.00571.x
    • (2009) Pediatric Diabetes , vol.10 , pp. 33-42
    • Hattersley, A.1    Bruining, J.2    Shield, J.3    Njolstad, P.4    Donaghue, K.C.5
  • 3
    • 77953032291 scopus 로고    scopus 로고
    • Pharmacogenetics for type 2 diabetes: Practical considerations for study design
    • 2-s2.0-77953032291
    • Vella A., Pharmacogenetics for type 2 diabetes: practical considerations for study design. Journal of Diabetes Science and Technology 2009 3 4 705 709 2-s2.0-77953032291
    • (2009) Journal of Diabetes Science and Technology , vol.3 , Issue.4 , pp. 705-709
    • Vella, A.1
  • 4
    • 77958172772 scopus 로고    scopus 로고
    • The effect of oral antidiabetic agents on A1C levels: A systematic review and meta-analysis
    • 2-s2.0-77958172772 10.2337/dc09-1727
    • Sherifali D., Nerenberg K., Pullenayegum E., Cheng J. E., Gerstein H. C., The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010 33 8 1859 1864 2-s2.0-77958172772 10.2337/dc09-1727
    • (2010) Diabetes Care , vol.33 , Issue.8 , pp. 1859-1864
    • Sherifali, D.1    Nerenberg, K.2    Pullenayegum, E.3    Cheng, J.E.4    Gerstein, H.C.5
  • 6
    • 60449089649 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy
    • 2-s2.0-60449089649 10.2337/dc08-9025
    • Nathan D. M., Buse J. B., Davidson M. B., Ferrannini E., Holman R. R., Sherwin R., Zinman B., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009 32 1 193 203 2-s2.0-60449089649 10.2337/dc08-9025
    • (2009) Diabetes Care , vol.32 , Issue.1 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3    Ferrannini, E.4    Holman, R.R.5    Sherwin, R.6    Zinman, B.7
  • 7
    • 0036231580 scopus 로고    scopus 로고
    • Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
    • DOI 10.1067/mcp.2002.122476
    • Kirchheiner J., Brockmöller J., Meineke I., Bauer S., Rohde W., Meisel C., Roots I., Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clinical Pharmacology and Therapeutics 2002 71 4 286 296 2-s2.0-0036231580 10.1067/mcp.2002.122476 (Pubitemid 34311458)
    • (2002) Clinical Pharmacology and Therapeutics , vol.71 , Issue.4 , pp. 286-296
    • Kirchheiner, J.1    Brockmoller, J.2    Meineke, I.3    Bauer, S.4    Rohde, W.5    Meisel, C.6    Roots, I.7
  • 8
    • 34548613766 scopus 로고    scopus 로고
    • Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination
    • DOI 10.1111/j.1365-2125.2007.02943.x
    • Elliot D. J., Suharjono S., Lewis B. C., Gillam E. M. J., Birkett D. J., Gross A. S., Miners J. O., Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. British Journal of Clinical Pharmacology 2007 64 4 450 457 2-s2.0-34548613766 10.1111/j.1365-2125.2007.02943.x (Pubitemid 47404317)
    • (2007) British Journal of Clinical Pharmacology , vol.64 , Issue.4 , pp. 450-457
    • Elliot, D.J.1    Suharjono, S.2    Lewis, B.C.3    Gillam, E.M.J.4    Birkett, D.J.5    Gross, A.S.6    Miners, J.O.7
  • 9
    • 21844466772 scopus 로고    scopus 로고
    • Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms [2]
    • DOI 10.1016/j.clpt.2005.03.008, PII S0009923605001384
    • Wang R., Chen K., Wen S.-Y., Li J., Wang S.-Q., Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clinical Pharmacology and Therapeutics 2005 78 1 90 92 2-s2.0-21844466772 10.1016/j.clpt.2005.03.008 (Pubitemid 40956936)
    • (2005) Clinical Pharmacology and Therapeutics , vol.78 , Issue.1 , pp. 90-92
    • Wang, R.1    Chen, K.2    Wen, S.-Y.3    Li, J.4    Wang, S.-Q.5
  • 10
    • 0036220552 scopus 로고    scopus 로고
    • Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers
    • DOI 10.1097/00008571-200203000-00004
    • Kirchheiner J., Bauer S., Meineke I., Rohde W., Prang V., Meisel C., Roots I., Brockmöller J., Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002 12 2 101 109 2-s2.0-0036220552 10.1097/00008571- 200203000-00004 (Pubitemid 34298914)
    • (2002) Pharmacogenetics , vol.12 , Issue.2 , pp. 101-109
    • Kirchheiner, J.1    Bauer, S.2    Meineke, I.3    Rohde, W.4    Prang, V.5    Meisel, C.6    Roots, I.7    Brockmoller, J.8
  • 11
    • 38349103468 scopus 로고    scopus 로고
    • Cytochrome P450 2C9 i2 and i3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus
    • 2-s2.0-38349103468 10.1038/sj.clpt.6100273
    • Becker M. L., Visser L. E., Trienekens P. H., Hofman A., Van Schaik R. H. N., Stricker B. H. C., Cytochrome P450 2C9 i2 and i3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clinical Pharmacology and Therapeutics 2008 83 2 288 292 2-s2.0-38349103468 10.1038/sj.clpt.6100273
    • (2008) Clinical Pharmacology and Therapeutics , vol.83 , Issue.2 , pp. 288-292
    • Becker, M.L.1    Visser, L.E.2    Trienekens, P.H.3    Hofman, A.4    Van Schaik, R.H.N.5    Stricker, B.H.C.6
  • 12
    • 78649710075 scopus 로고    scopus 로고
    • Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with type 2 diabetes mellitus
    • 2-s2.0-78649710075 10.2217/pgs.10.121
    • Swen J. J., Wessels J. A. M., Krabben A., Assendelft W. J. J., Guchelaar H.-J., Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with type 2 diabetes mellitus. Pharmacogenomics 2010 11 11 1517 1523 2-s2.0-78649710075 10.2217/pgs.10.121
    • (2010) Pharmacogenomics , vol.11 , Issue.11 , pp. 1517-1523
    • Swen, J.J.1    Wessels, J.A.M.2    Krabben, A.3    Assendelft, W.J.J.4    Guchelaar, H.-J.5
  • 13
    • 1842505044 scopus 로고    scopus 로고
    • Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers
    • DOI 10.2165/00003088-200443040-00005
    • Kirchheiner J., Meineke I., Müller G., Bauer S., Rohde W., Meisel C., Roots I., Brockmöller J., Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clinical Pharmacokinetics 2004 43 4 267 278 2-s2.0-1842505044 10.2165/00003088- 200443040-00005 (Pubitemid 38429306)
    • (2004) Clinical Pharmacokinetics , vol.43 , Issue.4 , pp. 267-278
    • Kirchheiner, J.1    Meineke, I.2    Muller, G.3    Bauer, S.4    Rohde, W.5    Meisel, C.6    Roots, I.7    Brockmoller, J.8
  • 14
    • 0042318871 scopus 로고    scopus 로고
    • CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
    • DOI 10.1046/j.0306-5251.2003.01862.x
    • Bidstrup T. B., Bjørnsdottir I., Sidelmann U. G., Thomsen M. S., Hansen K. T., CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. British Journal of Clinical Pharmacology 2003 56 3 305 314 2-s2.0-0042318871 10.1046/j.0306-5251.2003.01862.x (Pubitemid 37059658)
    • (2003) British Journal of Clinical Pharmacology , vol.56 , Issue.3 , pp. 305-314
    • Bidstrup, T.B.1    Bjornsdottir, I.2    Sidelmann, U.G.3    Thomsen, M.S.4    Hansen, K.T.5
  • 15
    • 39149108768 scopus 로고    scopus 로고
    • Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
    • DOI 10.1177/0091270007311569
    • Kalliokoski A., Neuvonen M., Neuvonen P. J., Niemi M., Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Journal of Clinical Pharmacology 2008 48 3 311 321 2-s2.0-39149108768 10.1177/0091270007311569 (Pubitemid 351257770)
    • (2008) Journal of Clinical Pharmacology , vol.48 , Issue.3 , pp. 311-321
    • Kalliokoski, A.1    Neuvonen, M.2    Neuvonen, P.J.3    Niemi, M.4
  • 16
    • 0030609143 scopus 로고    scopus 로고
    • Octameric stoichiometry of the K(ATP) channel complex
    • DOI 10.1085/jgp.110.6.655
    • Shyng S.-L., Nichols C. G., Octameric stoichiometry of the K(ATP) channel complex. Journal of General Physiology 1997 110 6 655 664 2-s2.0-0030609143 10.1085/jgp.110.6.655 (Pubitemid 27524606)
    • (1997) Journal of General Physiology , vol.110 , Issue.6 , pp. 655-664
    • Shyng, S.-L.1    Nichols, C.G.2
  • 17
    • 34547116194 scopus 로고    scopus 로고
    • Testing the bipartite model of the sulfonylurea receptor binding site: Binding of A-, B-, and a + B-site ligands
    • DOI 10.1124/jpet.107.123224
    • Winkler M., Stephan D., Bieger S., Kühner P., Wolff F., Quast U., Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and a + B-site ligands. Journal of Pharmacology and Experimental Therapeutics 2007 322 2 701 708 2-s2.0-34547116194 10.1124/jpet.107.123224 (Pubitemid 47105784)
    • (2007) Journal of Pharmacology and Experimental Therapeutics , vol.322 , Issue.2 , pp. 701-708
    • Winkler, M.1    Stephan, D.2    Bieger, S.3    Kuhner, P.4    Wolff, F.5    Quast, U.6
  • 18
    • 70349648967 scopus 로고    scopus 로고
    • Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K+ channel
    • 2-s2.0-70349648967 10.2337/db09-0143
    • Hamming K. S. C., Soliman D., Matemisz L. C., Niazi O., Lang Y., Gloyn A. L., Light P. E., Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K+ channel. Diabetes 2009 58 10 2419 2424 2-s2.0-70349648967 10.2337/db09-0143
    • (2009) Diabetes , vol.58 , Issue.10 , pp. 2419-2424
    • Hamming, K.S.C.1    Soliman, D.2    Matemisz, L.C.3    Niazi, O.4    Lang, Y.5    Gloyn, A.L.6    Light, P.E.7
  • 19
    • 85027917672 scopus 로고    scopus 로고
    • Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A
    • 2-s2.0-84855176516 10.1097/FPC.0b013e32835001e7
    • Lang V. Y., Fatehi M., Light P. E., Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenetics and Genomics 2012 22 3 206 214 2-s2.0-84855176516 10.1097/FPC.0b013e32835001e7
    • (2012) Pharmacogenetics and Genomics , vol.22 , Issue.3 , pp. 206-214
    • Lang, V.Y.1    Fatehi, M.2    Light, P.E.3
  • 23
    • 56149106823 scopus 로고    scopus 로고
    • Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients
    • 2-s2.0-56149106823 10.2337/dc07-2248
    • Feng Y., Mao G., Ren X., Xing H., Tang G., Li Q., Li X., Sun L., Yang J., Ma W., Wang X., Xu X., Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008 31 10 1939 1944 2-s2.0-56149106823 10.2337/dc07-2248
    • (2008) Diabetes Care , vol.31 , Issue.10 , pp. 1939-1944
    • Feng, Y.1    Mao, G.2    Ren, X.3    Xing, H.4    Tang, G.5    Li, Q.6    Li, X.7    Sun, L.8    Yang, J.9    Ma, W.10    Wang, X.11    Xu, X.12
  • 24
    • 34247144968 scopus 로고    scopus 로고
    • Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes
    • DOI 10.1016/j.diabres.2006.10.021, PII S016882270600492X
    • Zhang H., Liu X., Kuang H., Yi R., Xing H., Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Research and Clinical Practice 2007 77 1 58 61 2-s2.0-34247144968 10.1016/j.diabres.2006.10.021 (Pubitemid 46590477)
    • (2007) Diabetes Research and Clinical Practice , vol.77 , Issue.1 , pp. 58-61
    • Zhang, H.1    Liu, X.2    Kuang, H.3    Yi, R.4    Xing, H.5
  • 26
    • 0035043009 scopus 로고    scopus 로고
    • Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)
    • DOI 10.1046/j.1464-5491.2001.00449.x
    • Gloyn A. L., Hashim Y., Ashcroft S. J. H., Ashfield R., Wiltshire S., Turner R. C., Association studies of variants in promoter and coding regions of beta-cell ATP sensitive K-channel genes SUR1 and Kir6.2 with type 2 diabetes mellitus (UKPDS 53). Diabetic Medicine 2001 18 3 206 212 2-s2.0-0037349226 10.1046/j.1464-5491.2003.00944.x (Pubitemid 32397858)
    • (2001) Diabetic Medicine , vol.18 , Issue.3 , pp. 206-212
    • Gloyn, A.L.1    Hashim, Y.2    Ashcroft, S.J.H.3    Ashfield, R.4    Wiltshire, S.5    Turner, R.C.6
  • 27
    • 33744965950 scopus 로고    scopus 로고
    • The E23K variant of KCNJ11 encoding the pancreatic β-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes
    • DOI 10.1210/jc.2005-2323
    • Sesti G., Laratta E., Cardellini M., Andreozzi F., Del Guerra S., Irace C., Gnasso A., Grupillo M., Lauro R., Hribal M. L., Perticone F., Marchetti P., The E23K variant of KCNJ11 encoding the pancreatic β -cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2006 91 6 2334 2339 2-s2.0-33744965950 10.1210/jc.2005-2323 (Pubitemid 43855025)
    • (2006) Journal of Clinical Endocrinology and Metabolism , vol.91 , Issue.6 , pp. 2334-2339
    • Sesti, G.1    Laratta, E.2    Cardellini, M.3    Andreozzi, F.4    Del Guerra, S.5    Irace, C.6    Gnasso, A.7    Grupillo, M.8    Lauro, R.9    Hribal, M.L.10    Perticone, F.11    Marchetti, P.12
  • 28
    • 49249118751 scopus 로고    scopus 로고
    • Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients
    • 2-s2.0-49249118751 10.1111/j.1745-7254.2008.00840.x
    • He Y.-Y., Zhang R., Shao X.-Y., Hu C., Wang C.-R., Lu J.-X., Bao Y.-Q., Jia W.-P., Xiang K.-S., Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta Pharmacologica Sinica 2008 29 8 983 989 2-s2.0-49249118751 10.1111/j.1745-7254.2008.00840.x
    • (2008) Acta Pharmacologica Sinica , vol.29 , Issue.8 , pp. 983-989
    • He, Y.-Y.1    Zhang, R.2    Shao, X.-Y.3    Hu, C.4    Wang, C.-R.5    Lu, J.-X.6    Bao, Y.-Q.7    Jia, W.-P.8    Xiang, K.-S.9
  • 30
    • 61849101938 scopus 로고    scopus 로고
    • Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: A large Human Genome Epidemiology (HuGE) review and meta-analysis
    • 2-s2.0-61849101938 10.1186/1471-2350-10-15
    • Tong Y., Lin Y., Zhang Y., Yang J., Zhang Y., Liu H., Zhang B., Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Medical Genetics 2009 10, article 15 2-s2.0-61849101938 10.1186/1471-2350-10-15
    • (2009) BMC Medical Genetics , vol.1015
    • Tong, Y.1    Lin, Y.2    Zhang, Y.3    Yang, J.4    Zhang, Y.5    Liu, H.6    Zhang, B.7
  • 31
    • 12544254474 scopus 로고    scopus 로고
    • TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β -catenin and glycogen synthase kinase-3 β
    • 2-s2.0-12544254474 10.1074/jbc.M411487200
    • Yi F., Brubaker P. L., Jin T., TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β -catenin and glycogen synthase kinase-3 β The Journal of Biological Chemistry 2005 280 2 1457 1464 2-s2.0-12544254474 10.1074/jbc.M411487200
    • (2005) The Journal of Biological Chemistry , vol.280 , Issue.2 , pp. 1457-1464
    • Yi, F.1    Brubaker, P.L.2    Jin, T.3
  • 34
    • 67349270566 scopus 로고    scopus 로고
    • Translating TCF7L2: From gene to function
    • 2-s2.0-67349270566 10.1007/s00125-009-1356-1
    • Pearson E. R., Translating TCF7L2: from gene to function. Diabetologia 2009 52 7 1227 1230 2-s2.0-67349270566 10.1007/s00125-009-1356-1
    • (2009) Diabetologia , vol.52 , Issue.7 , pp. 1227-1230
    • Pearson, E.R.1
  • 35
    • 77449099615 scopus 로고    scopus 로고
    • TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action
    • 2-s2.0-77449099615 10.2337/db09-1169
    • Villareal D. T., Robertson H., Bell G. I., Patterson B. W., Tran H., Wice B., Polonsky K. S., TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010 59 2 479 485 2-s2.0-77449099615 10.2337/db09-1169
    • (2010) Diabetes , vol.59 , Issue.2 , pp. 479-485
    • Villareal, D.T.1    Robertson, H.2    Bell, G.I.3    Patterson, B.W.4    Tran, H.5    Wice, B.6    Polonsky, K.S.7
  • 37
    • 84874894776 scopus 로고    scopus 로고
    • Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide
    • 374858 10.1155/2013/374858
    • Javorský M., Babjaková E., Klimčáková L., Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide. International Journal of Endocrinology 2013 2013 5 374858 10.1155/2013/374858
    • (2013) International Journal of Endocrinology , vol.2013 , pp. 5
    • Javorský, M.1    Babjaková, E.2    Klimčáková, L.3
  • 38
    • 79951960556 scopus 로고    scopus 로고
    • TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes
    • 2-s2.0-79951960556 10.1186/1471-2350-12-30
    • Holstein A., Hahn M., Körner A., Stumvoll M., Kovacs P., TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Medical Genetics 2011 12, article 30 2-s2.0-79951960556 10.1186/1471-2350-12-30
    • (2011) BMC Medical Genetics , vol.1230
    • Holstein, A.1    Hahn, M.2    Körner, A.3    Stumvoll, M.4    Kovacs, P.5
  • 42
    • 84865457823 scopus 로고    scopus 로고
    • The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program
    • Florez J. C., Jablonski K. A., Taylor A., The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care 2012 35 9 1864 1867
    • (2012) Diabetes Care , vol.35 , Issue.9 , pp. 1864-1867
    • Florez, J.C.1    Jablonski, K.A.2    Taylor, A.3
  • 45
    • 44949087480 scopus 로고    scopus 로고
    • Polymorphism in human organic cation transporters and metformin action
    • DOI 10.2217/14622416.9.4.415
    • Takane H., Shikata E., Otsubo K., Higuchi S., Ieiri I., Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008 9 4 415 422 2-s2.0-44949087480 10.2217/14622416.9.4.415 (Pubitemid 351803926)
    • (2008) Pharmacogenomics , vol.9 , Issue.4 , pp. 415-422
    • Takane, H.1    Shikata, E.2    Otsubo, K.3    Higuchi, S.4    Ieiri, I.5
  • 46
    • 70350075408 scopus 로고    scopus 로고
    • Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver
    • 2-s2.0-70350075408 10.1002/hep.23103
    • Nies A. T., Koepsell H., Winter S., Burk O., Klein K., Kerb R., Zanger U. M., Keppler D., Schwab M., Schaeffeler E., Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009 50 4 1227 1240 2-s2.0-70350075408 10.1002/hep.23103
    • (2009) Hepatology , vol.50 , Issue.4 , pp. 1227-1240
    • Nies, A.T.1    Koepsell, H.2    Winter, S.3    Burk, O.4    Klein, K.5    Kerb, R.6    Zanger, U.M.7    Keppler, D.8    Schwab, M.9    Schaeffeler, E.10
  • 48
    • 66649121405 scopus 로고    scopus 로고
    • Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: A GoDARTS study
    • 2-s2.0-66649121405 10.2337/db08-0896
    • Zhou K., Donnelly L. A., Kimber C. H., Donnan P. T., Doney A. S. F., Leese G., Hattersley A. T., McCarthy M. I., Morris A. D., Palmer C. N. A., Pearson E. R., Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 2009 58 6 1434 1439 2-s2.0-66649121405 10.2337/db08-0896
    • (2009) Diabetes , vol.58 , Issue.6 , pp. 1434-1439
    • Zhou, K.1    Donnelly, L.A.2    Kimber, C.H.3    Donnan, P.T.4    Doney, A.S.F.5    Leese, G.6    Hattersley, A.T.7    McCarthy, M.I.8    Morris, A.D.9    Palmer, C.N.A.10    Pearson, E.R.11
  • 49
    • 81055140250 scopus 로고    scopus 로고
    • The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
    • 2-s2.0-81055140250 10.1097/FPC.0b013e32834c0010
    • Christensen M. M. H., Brasch-Andersen C., Green H., Nielsen F., Damkier P., Beck-Nielsen H., Brosen K., The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenetics and Genomics 2011 21 12 837 850 2-s2.0-81055140250 10.1097/FPC.0b013e32834c0010
    • (2011) Pharmacogenetics and Genomics , vol.21 , Issue.12 , pp. 837-850
    • Christensen, M.M.H.1    Brasch-Andersen, C.2    Green, H.3    Nielsen, F.4    Damkier, P.5    Beck-Nielsen, H.6    Brosen, K.7
  • 50
    • 67849116869 scopus 로고    scopus 로고
    • Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus
    • 2-s2.0-67849116869 10.1038/tpj.2009.15
    • Becker M. L., Visser L. E., van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics Journal 2009 9 4 242 247 2-s2.0-67849116869 10.1038/tpj.2009.15
    • (2009) Pharmacogenomics Journal , vol.9 , Issue.4 , pp. 242-247
    • Becker, M.L.1    Visser, L.E.2    Van Schaik, R.H.N.3    Hofman, A.4    Uitterlinden, A.G.5    Stricker, B.H.C.6
  • 51
    • 84864950319 scopus 로고    scopus 로고
    • Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients
    • Tarasova L., Kalnina I., Geldnere K., Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenetics and Genomics 2012 22 9 659 666
    • (2012) Pharmacogenetics and Genomics , vol.22 , Issue.9 , pp. 659-666
    • Tarasova, L.1    Kalnina, I.2    Geldnere, K.3
  • 52
    • 76949107912 scopus 로고    scopus 로고
    • SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin
    • 2-s2.0-76949107912 10.1038/aps.2009.189
    • Li Q., Liu F., Zheng T.-S., Tang J.-L., Lu H.-J., Jia W.-P., SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacologica Sinica 2010 31 2 184 190 2-s2.0-76949107912 10.1038/aps.2009.189
    • (2010) Acta Pharmacologica Sinica , vol.31 , Issue.2 , pp. 184-190
    • Li, Q.1    Liu, F.2    Zheng, T.-S.3    Tang, J.-L.4    Lu, H.-J.5    Jia, W.-P.6
  • 53
    • 54249106729 scopus 로고    scopus 로고
    • Genetic variants of the organic cation transporter 2 influence the disposition of metformin
    • 2-s2.0-54249106729 10.1038/clpt.2008.61
    • Song I. S., Shin H. J., Shim E. J., Jung I. S., Kim W. Y., Shon J. H., Shin J. G., Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clinical Pharmacology and Therapeutics 2008 84 5 559 562 2-s2.0-54249106729 10.1038/clpt.2008.61
    • (2008) Clinical Pharmacology and Therapeutics , vol.84 , Issue.5 , pp. 559-562
    • Song, I.S.1    Shin, H.J.2    Shim, E.J.3    Jung, I.S.4    Kim, W.Y.5    Shon, J.H.6    Shin, J.G.7
  • 54
    • 53049095113 scopus 로고    scopus 로고
    • OCT2 polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine
    • 2-s2.0-53049095113 10.1097/FPC.0b013e328302cd41
    • Wang Z.-J., Yin O. Q. P., Tomlinson B., Chow M. S. S., OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenetics and Genomics 2008 18 7 637 645 2-s2.0-53049095113 10.1097/FPC.0b013e328302cd41
    • (2008) Pharmacogenetics and Genomics , vol.18 , Issue.7 , pp. 637-645
    • Wang, Z.-J.1    Yin, O.Q.P.2    Tomlinson, B.3    Chow, M.S.S.4
  • 56
    • 62749133967 scopus 로고    scopus 로고
    • Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study
    • 2-s2.0-62749133967 10.2337/db08-1028
    • Becker M. L., Visser L. E., van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009 58 3 745 749 2-s2.0-62749133967 10.2337/db08-1028
    • (2009) Diabetes , vol.58 , Issue.3 , pp. 745-749
    • Becker, M.L.1    Visser, L.E.2    Van Schaik, R.H.N.3    Hofman, A.4    Uitterlinden, A.G.5    Stricker, B.H.C.6
  • 57
    • 73949087018 scopus 로고    scopus 로고
    • Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response
    • 2-s2.0-73949087018 10.1097/FPC.0b013e328333bb11
    • Becker M. L., Visser L. E., van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenetics and Genomics 2010 20 1 38 44 2-s2.0-73949087018 10.1097/FPC.0b013e328333bb11
    • (2010) Pharmacogenetics and Genomics , vol.20 , Issue.1 , pp. 38-44
    • Becker, M.L.1    Visser, L.E.2    Van Schaik, R.H.N.3    Hofman, A.4    Uitterlinden, A.G.5    Stricker, B.H.C.6
  • 59
    • 84871937263 scopus 로고    scopus 로고
    • Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes
    • Tkáč I., Klimčáková L., Javorský M., Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obesity and Metabolism 2012 15 2 189 191
    • (2012) Diabetes Obesity and Metabolism , vol.15 , Issue.2 , pp. 189-191
    • Tkáč, I.1    Klimčáková, L.2    Javorský, M.3
  • 60
    • 84872679649 scopus 로고    scopus 로고
    • The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin
    • Stocker S. L., Morrissey K. M., Yee S. W., The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clinical Pharmacology and Therapeutics 2013 93 2 186 194
    • (2013) Clinical Pharmacology and Therapeutics , vol.93 , Issue.2 , pp. 186-194
    • Stocker, S.L.1    Morrissey, K.M.2    Yee, S.W.3
  • 63
    • 37549040583 scopus 로고    scopus 로고
    • Trimethoprim and the CYP2C8i3 allele have opposite effects on the pharmacokinetics of pioglitazone
    • 2-s2.0-37549040583 10.1124/dmd.107.018010
    • Tornio A., Niemi M., Neuvonen P. J., Backman J. T., Trimethoprim and the CYP2C8i3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metabolism and Disposition 2008 36 1 73 80 2-s2.0-37549040583 10.1124/dmd.107.018010
    • (2008) Drug Metabolism and Disposition , vol.36 , Issue.1 , pp. 73-80
    • Tornio, A.1    Niemi, M.2    Neuvonen, P.J.3    Backman, J.T.4
  • 64
    • 79952837092 scopus 로고    scopus 로고
    • Discovery of a novel allelic variant of CYP2C8, CYP2C8i11, in asian populations and its clinical effect on the rosiglitazone disposition in vivo
    • 2-s2.0-79952837092 10.1124/dmd.110.035899
    • Yeo C.-W., Lee S.-J., Lee S. S., Bae S. K., Kim E.-Y., Shon J.-H., Rhee B. D., Shin J.-G., Discovery of a novel allelic variant of CYP2C8, CYP2C8i11, in asian populations and its clinical effect on the rosiglitazone disposition in vivo. Drug Metabolism and Disposition 2011 39 4 711 716 2-s2.0-79952837092 10.1124/dmd.110.035899
    • (2011) Drug Metabolism and Disposition , vol.39 , Issue.4 , pp. 711-716
    • Yeo, C.-W.1    Lee, S.-J.2    Lee, S.S.3    Bae, S.K.4    Kim, E.-Y.5    Shon, J.-H.6    Rhee, B.D.7    Shin, J.-G.8
  • 65
    • 84874945128 scopus 로고    scopus 로고
    • The role of genetic variants in CYP2C8, LPIN1, PPARGCA and PPAR γ on the trough steady state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes
    • Stage T. B., Christensen M. M. H., Federsen S., Beck-Nielsen H., Brøsen K., The role of genetic variants in CYP2C8, LPIN1, PPARGCA and PPAR γ on the trough steady state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenetics and Genomics 2013 22 4 219 227
    • (2013) Pharmacogenetics and Genomics , vol.22 , Issue.4 , pp. 219-227
    • Stage, T.B.1    Christensen, M.M.H.2    Federsen, S.3    Beck-Nielsen, H.4    Brøsen, K.5
  • 66
    • 0345164399 scopus 로고    scopus 로고
    • Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: Identification of a Pro12Ala PPARγ2 missense mutation
    • DOI 10.1006/bbrc.1997.7798
    • Chung-Jen Y., Beamer B. A., Negri C., Silver K., Brown K. A., Yarnall D. P., Burns D. K., Roth J., Shuldiner A. R., Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPAR γ) gene in diabetic Caucasians: identification of a Pro12Ala PPAR γ 2 missense mutation. Biochemical and Biophysical Research Communications 1997 241 2 270 274 2-s2.0-0345164399 10.1006/bbrc.1997.7798 (Pubitemid 28020091)
    • (1997) Biochemical and Biophysical Research Communications , vol.241 , Issue.2 , pp. 270-274
    • Chung-Jen, Y.1    Beamer, B.A.2    Negri, C.3    Silver, K.4    Brown, K.A.5    Yarnall, D.P.6    Burns, D.K.7    Roth, J.8    Shuldiner, A.R.9
  • 67
    • 77949397703 scopus 로고    scopus 로고
    • The association between the peroxisome proliferator-activated receptor- γ 2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: A HuGE review and meta-analysis
    • 2-s2.0-77949397703 10.1093/aje/kwp450
    • Gouda H. N., Sagoo G. S., Harding A.-H., Yates J., Sandhu M. S., Higgins J. P. T., The association between the peroxisome proliferator-activated receptor- γ 2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. American Journal of Epidemiology 2010 171 6 645 655 2-s2.0-77949397703 10.1093/aje/kwp450
    • (2010) American Journal of Epidemiology , vol.171 , Issue.6 , pp. 645-655
    • Gouda, H.N.1    Sagoo, G.S.2    Harding, A.-H.3    Yates, J.4    Sandhu, M.S.5    Higgins, J.P.T.6
  • 68
    • 77955481012 scopus 로고    scopus 로고
    • Common polymorphisms of the peroxisome proliferator-activated receptor- γ (Pro12Ala) and peroxisome proliferator-activated receptor- γ coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus
    • 2-s2.0-77955481012 10.1016/j.metabol.2009.10.030
    • Hsieh M.-C., Lin K.-D., Tien K.-J., Tu S.-T., Hsiao J.-Y., Chang S.-J., Lin S.-R., Shing S.-J., Chen H.-C., Common polymorphisms of the peroxisome proliferator-activated receptor- γ (Pro12Ala) and peroxisome proliferator-activated receptor- γ coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism 2010 59 8 1139 1144 2-s2.0-77955481012 10.1016/j.metabol.2009.10.030
    • (2010) Metabolism , vol.59 , Issue.8 , pp. 1139-1144
    • Hsieh, M.-C.1    Lin, K.-D.2    Tien, K.-J.3    Tu, S.-T.4    Hsiao, J.-Y.5    Chang, S.-J.6    Lin, S.-R.7    Shing, S.-J.8    Chen, H.-C.9
  • 69
    • 23444457610 scopus 로고    scopus 로고
    • Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes
    • DOI 10.1016/j.clpt.2005.04.013, PII S0009923605001864
    • Kang E. S., Park S. Y., Kim H. J., Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ 2 gene on rosiglitazone response in type 2 diabetes. Clinical Pharmacology and Therapeutics 2005 78 2 202 208 2-s2.0-23444457610 10.1016/j.clpt.2005.04.013 (Pubitemid 41112288)
    • (2005) Clinical Pharmacology and Therapeutics , vol.78 , Issue.2 , pp. 202-208
    • Eun, S.K.1    So, Y.P.2    Hyeong, J.K.3    Chul, S.K.4    Chul, W.A.5    Bong, S.C.6    Sung, K.L.7    Chung, M.N.8    Hyun, C.L.9
  • 71
    • 18344417084 scopus 로고    scopus 로고
    • Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes
    • DOI 10.2337/diacare.26.3.825
    • Blüher M., Lübben G., Paschke R., Analysis of the relationship between the Pro12Ala variant in the PPAR- γ 2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003 26 3 825 831 2-s2.0-18344417084 10.2337/diacare.26.3.825 (Pubitemid 36929350)
    • (2003) Diabetes Care , vol.26 , Issue.3 , pp. 825-831
    • Bluher, M.1    Lubben, G.2    Paschke, R.3
  • 72
    • 80455160172 scopus 로고    scopus 로고
    • Polymorphism of peroxisome proliferator-activated receptor γ (PPAR γ) Pro12Ala in the Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes
    • 2-s2.0-80455160172 10.1016/j.ejphar.2011.09.158
    • Namvaran F., Azarpira N., Rahimi-Moghaddam P., Dabbaghmanesh M. H., Polymorphism of peroxisome proliferator-activated receptor γ (PPAR γ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. European Journal of Pharmacology 2011 671 1-3 1 6 2-s2.0-80455160172 10.1016/j.ejphar.2011.09. 158
    • (2011) European Journal of Pharmacology , vol.671 , Issue.1-3 , pp. 1-6
    • Namvaran, F.1    Azarpira, N.2    Rahimi-Moghaddam, P.3    Dabbaghmanesh, M.H.4
  • 73
    • 18144431682 scopus 로고    scopus 로고
    • The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes
    • DOI 10.2337/diacare.28.5.1139
    • Eun S. K., So Y. P., Hyeong J. K., Chul W. A., Nam M., Bong S. C., Sung K. L., Kyung R. K., Hyun C. L., The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005 28 5 1139 1144 2-s2.0-18144431682 10.2337/diacare.28.5.1139 (Pubitemid 40616625)
    • (2005) Diabetes Care , vol.28 , Issue.5 , pp. 1139-1144
    • Eun, S.K.1    So, Y.P.2    Hyeong, J.K.3    Chul, W.A.4    Nam, M.5    Bong, S.C.6    Sung, K.L.7    Kyung, R.K.8    Hyun, C.L.9
  • 74
    • 50249133701 scopus 로고    scopus 로고
    • The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes
    • 2-s2.0-50249133701 10.1111/j.1463-1326.2008.00905.x
    • Li Z., Peng X., Wu Y., Xia Y., Liu X., Zhang Q., The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes. Diabetes, Obesity and Metabolism 2008 10 9 794 802 2-s2.0-50249133701 10.1111/j.1463-1326.2008.00905.x
    • (2008) Diabetes, Obesity and Metabolism , vol.10 , Issue.9 , pp. 794-802
    • Li, Z.1    Peng, X.2    Wu, Y.3    Xia, Y.4    Liu, X.5    Zhang, Q.6
  • 75
    • 84863766951 scopus 로고    scopus 로고
    • Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus
    • 2-s2.0-83655181377 10.1007/s11033-011-1354-5
    • Namvaran F., Rahimi-Moghaddam P., Azarpira N., Dabbaghmanesh M. H., Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus. Molecular Biology Reports 2012 39 5 5511 5518 2-s2.0-83655181377 10.1007/s11033-011-1354-5
    • (2012) Molecular Biology Reports , vol.39 , Issue.5 , pp. 5511-5518
    • Namvaran, F.1    Rahimi-Moghaddam, P.2    Azarpira, N.3    Dabbaghmanesh, M.H.4
  • 76
    • 33846006173 scopus 로고    scopus 로고
    • The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    • DOI 10.1016/S0140-6736(06)69705-5, PII S0140673606697055
    • Drucker D. J., Nauck M. A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet 2006 368 9548 1696 1705 2-s2.0-33846006173 10.1016/S0140-6736(06)69705-5 (Pubitemid 46048557)
    • (2006) Lancet , vol.368 , Issue.9548 , pp. 1696-1705
    • Drucker, D.J.1    Nauck, M.A.2
  • 78
    • 75749091912 scopus 로고    scopus 로고
    • Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge
    • Saxena R., Hivert M. F., Langenberg C., Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nature Genetics 2010 42 2 142 148
    • (2010) Nature Genetics , vol.42 , Issue.2 , pp. 142-148
    • Saxena, R.1    Hivert, M.F.2    Langenberg, C.3
  • 80
    • 84871179193 scopus 로고    scopus 로고
    • Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7904146 risk T allele
    • Færch K., Pilgaard K., Knop F. K., Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7904146 risk T allele. Diabetes, Obesity and Metabolism 2013 15 1 91 95
    • (2013) Diabetes, Obesity and Metabolism , vol.15 , Issue.1 , pp. 91-95
    • Færch, K.1    Pilgaard, K.2    Knop, F.K.3
  • 81
    • 77449099615 scopus 로고    scopus 로고
    • TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action
    • 2-s2.0-77449099615 10.2337/db09-1169
    • Villareal D. T., Robertson H., Bell G. I., Patterson B. W., Tran H., Wice B., Polonsky K. S., TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010 59 2 479 485 2-s2.0-77449099615 10.2337/db09-1169
    • (2010) Diabetes , vol.59 , Issue.2 , pp. 479-485
    • Villareal, D.T.1    Robertson, H.2    Bell, G.I.3    Patterson, B.W.4    Tran, H.5    Wice, B.6    Polonsky, K.S.7
  • 83
    • 67349190497 scopus 로고    scopus 로고
    • A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion
    • 2-s2.0-67349190497 10.1007/s00125-009-1344-5
    • Schäfer S. A., Müssig K., Staiger H., MacHicao F., Stefan N., Gallwitz B., Häring H. U., Fritsche A., A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia 2009 52 6 1075 1082 2-s2.0-67349190497 10.1007/s00125-009-1344-5
    • (2009) Diabetologia , vol.52 , Issue.6 , pp. 1075-1082
    • Schäfer, S.A.1    Müssig, K.2    Staiger, H.3    Machicao, F.4    Stefan, N.5    Gallwitz, B.6    Häring, H.U.7    Fritsche, A.8
  • 84
    • 84860588948 scopus 로고    scopus 로고
    • Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1
    • 2-s2.0-84860588948 10.2337/db11-1732
    • Smushkin G., Sathananthan M., Sathananthan A., Man C. D., Micheletto F., Zinsmeister A. R., Cobelli C., Vella A., Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1. Diabetes 2012 61 5 1082 1089 2-s2.0-84860588948 10.2337/db11-1732
    • (2012) Diabetes , vol.61 , Issue.5 , pp. 1082-1089
    • Smushkin, G.1    Sathananthan, M.2    Sathananthan, A.3    Man, C.D.4    Micheletto, F.5    Zinsmeister, A.R.6    Cobelli, C.7    Vella, A.8
  • 85
    • 84885215197 scopus 로고    scopus 로고
    • The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway
    • 't Haart L. M., Fritsche A., Nijpels G., The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes 2013 62 9 3275 3281
    • (2013) Diabetes , vol.62 , Issue.9 , pp. 3275-3281
    • 'T Haart, L.M.1    Fritsche, A.2    Nijpels, G.3
  • 86
    • 84858798082 scopus 로고    scopus 로고
    • Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing
    • 2-s2.0-84858798082 10.1038/clpt.2011.355
    • Martin M. A., Klein T. E., Dong B. J., Pirmohamed M., Haas D. W., Kroetz D. L., Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clinical Pharmacology and Therapeutics 2012 91 4 734 738 2-s2.0-84858798082 10.1038/clpt.2011.355
    • (2012) Clinical Pharmacology and Therapeutics , vol.91 , Issue.4 , pp. 734-738
    • Martin, M.A.1    Klein, T.E.2    Dong, B.J.3    Pirmohamed, M.4    Haas, D.W.5    Kroetz, D.L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.